GlassScriptPhysician profile
Charles D Lafleur
NPI 1962057950
$4,996.10
in general payments reported to CMS, 2019-2025
26 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,624 · 2022: $1,791 · 2023: $22.60 · 2024: $189 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $979 · Education: $392 · Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $978.65 |
| Education | $391.96 |
| Food and Beverage | $211.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,134.63 | 2025 | Interstim |
| Sk Life Science, INC. | $583.46 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $384.12 | 2021-2023 | Nuplazid |
| Astellas Pharma US INC | $364.96 | 2024-2025 | |
| Amgen INC. | $303.60 | 2021-2022 | |
| Genzyme Corporation | $249.60 | 2021-2022 | |
| Lilly USA, LLC | $234.81 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $217.18 | 2021-2022 | |
| Abbvie INC. | $206.44 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $182.67 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $180.61 | 2022 | |
| Biogen, INC. | $128.48 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $125.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $119.79 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $94.26 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $91.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $90.11 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.56 | 2022 | |
| Supernus Pharmaceuticals, INC. | $48.61 | 2021-2022 | |
| Ge Healthcare | $38.25 | 2022 | |
| Ucb, INC. | $30.62 | 2021 | |
| Eisai INC. | $25.86 | 2022 | |
| Endo USA, INC. | $24.12 | 2024 | Aveed |
| 180 Medical, INC. | $19.07 | 2025 | Gentlecath Glide |
| Vertex Pharmaceuticals Incorporated | $16.53 | 2025 | |
| Avion Pharmaceuticals | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lafleur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.